Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase

Advances in Enzyme Regulation

Volumn 46, Issue 1, 2006, Pages 235-247

  Yen, Yun ^a   Chu, Bernard ^a   Yen, Christina ^a   Shih, Jennifer ^a   Zhou, Bingsen ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; PROTEIN SUBUNIT; RIBONUCLEOTIDE REDUCTASE; RRM2B PROTEIN, HUMAN;

ARTICLE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; PHYSIOLOGY;

CELL CYCLE PROTEINS; HUMANS; PROTEIN SUBUNITS; RIBONUCLEOTIDE REDUCTASES;

EID: 33748085352     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2006.01.016     Document Type: Article

References (29)

1. Adrait A., Ohrstrom M., Barra A.L., Thelander L., and Graslund A. EPR studies on a stable sulfinyl radical observed in the iron-oxygen-reconstituted Y177F/I263C protein R2 double mutant of ribonucleotide reductase from mouse. Biochem 41 (2002) 6510-6516
2. Bollinger Jr. J.M., Edmondson D.E., Huynh B.H., Filley J., Norton J.R., and Stubbe J. Mechanism of assembly of the tyrosyl radical-dinuclear iron cluster cofactor of ribonucleotide reductase. Science 253 (1991) 292-298
3. Chabes A., Pfleger C.M., Kirschner M.W., and Thelander L. Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci USA 100 (2003) 3925-3929
4. Chaston T.B., Lovejoy D.B., Watts R.N., and Richardson D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9 (2003) 402-414
5. Climent I., Sjoberg B.M., and Huang C.Y. Site-directed mutagenesis and deletion of the carboxyl terminus of escherichia coli ribonucleotide reductase protein R2. Effects on catalytic activity and subunit interaction. Biochemistry 31 (1992) 4801-4807
6. Eklund H., Uhlin U., Farnegardh M., Logan D.T., and Nordlund P. Structure and function of the radical enzyme ribonucleotide reductase. Prog Biophys Mol Biol 77 (2001) 177-268
7. Fan H., Villegas C., Huang A., and Wright J.A. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58 (1998) 1650-1653
8. Finch R.A., Liu M.C., Cory A.H., Cory J.G., and Sartorelli A.C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 39 (1999) 3-12
9. Guittet O., Hakansson P., Voevodskaya N., Fridd S., Graslund A., Arakawa H., et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276 (2001) 40647-40651
10. Henriksen M.A., Cooperman B.S., Salem J.S., Li L.-S., and Rubin H. The stable tyrosyl radical in mouse ribonucleotide reductase is not essential for enzymatic activity. J Am Chem Soc 116 (1994) 9773-9774
11. Jordan A., and Reichard P. Ribonucleotide reductases. Annu Rev Biochem 67 (1998) 71-98
12. Kauppi B., Nielsen B.B., Ramaswamy S., Larsen I.K., Thelander M., Thelander L., et al. The three-dimensional structure of mammalian ribonucleotide reductase protein R2 reveals a more-accessible iron-radical site than escherichia coli R2. J Mol Biol 262 (1996) 706-720
13. Kimura T., Takeda S., Sagiya Y., Gotoh M., Nakamura Y., and Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet (2003) (Epub ahead of print on PubMed)
14. Lozano G., and Elledge S.J. p53 sends nucleotides to repair DNA. Nature 404 (2000) 24-25
15. Mann G.J., Graslund A., Ochiai E., Ingemarson R., and Thelander L. Purification and characterization of recombinant mouse and herpes simplex virus ribonucleotide reductase R2 subunit. Biochem 30 (1991) 1939-1947
16. Nakano K., Balint E., Ashcroft M., and Vousden K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19 (2000) 4283-4289
17. Nyholm S., Mann G.J., Johansson A.G., Bergeron R.J., Graslund A., and Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 268 (1993) 26200-26205
18. Ren S., Wang R., Komatsu K., Bonaz-Krause P., Zyrianov Y., McKenna C.E., et al. Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents. J Med Chem 45 (2002) 410-419
19. Richardson D.R. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol 42 (2002) 267-281
20. Rova U., Adrait A., Potsch S., Graslund A., and Thelander L. Evidence by mutagenesis that Tyr370 of the mouse ribonucleotide reductase R2 protein is the connecting link in the intersubunit radical transfer pathway. J Biol Chem 274 (1999) 23746-23751
21. Sahlin M., Lassmann G., Potsch S., Slaby A., Sjoberg B.M., and Graslund A. Tryptophan radicals formed by iron/oxygen reaction with Escherichia coli ribonucleotide reductase protein R2 mutant Y122F. J Biol Chem 269 (1994) 11699-11702
22. Shao J., Zhou B., Zhu L., Qiu W., Yuan Y., Xi B., and Yen Y. In vitro characterization of enzyme properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 64 (2004) 1-6
23. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., and Nakamura Y.A. Ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42-49
24. Xue L., Zhou B., Liu X., Qiu W., Jin Z., and Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res 63 (2003) 980-986
25. Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., and Arakawa H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 61 (2001) 8256-8262
26. Yen Y., Grill S.P., Dutschman G.E., Chang C.N., Zhou B.S., and Cheng Y.C. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res 54 (1994) 3686-3691
27. Zhou B.S., Hsu N.Y., Pan B.C., Doroshow J.H., and Yen Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 55 (1995) 1328-1333
28. Zhou B., Liu X., Mo X., Xue L., Darwish D., Qiu W., Shih J., Hwu E.B., Luh F., and Yen Y. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res 63 (2003) 6583-6594
29. Zhou B.S., Tsai P., Ker R., Tsai J., Ho R., Yu J., Shih J., and Yen Y. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16 (1995) 43-49